05:00 AM EDT, 08/04/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lift our target to $443 from $367 based on our net present value (NPV) analysis. We lower our 2025 EPS estimate to $0.87 from $1.15 and our 2026 EPS view to $3.23 from $3.95. Alnylam Pharmaceuticals ( ALNY ) delivered strong Q2 2025 results, marking a significant commercial inflection driven by Amvuttra's successful expansion into the ATTR-CM indication, in our view. Q2 total net product revenues of $672.2M (+64% Y/Y), substantially outpaced prior performance and demonstrated the strength of the RNAi therapeutic portfolio, in our view. The TTR franchise generated $544.5M (+77% Y/Y) in sales, with Amvuttra contributing $492M (+114% Y/Y) as the therapy gained strong traction in both polyneuropathy and cardiomyopathy indications. ALNY's rare disease franchise also demonstrated solid momentum, with Givlaari revenues up 30% Y/Y and Oxlumo sales rising by 15% Y/Y. We expect the strong commercial performance seen in Q2 to continue in the back half of the year and now forecast full year total sales to rise by 56% Y/Y.